Neu auf wallstreet:online? Jetzt kostenlos registrieren!
Registrieren | Login
x
Benutzername:

Passwort:

Angemeldet bleiben
Passwort vergessen?

    OctoPlus publishes Annual Report and AGM documents

    Nachrichtenquelle: GlobeNewswire
     |  27.04.2012, 18:31  |  402 Aufrufe  |   | 


    OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO) announces today the
    publication of its Annual Report 2011. The Annual Report is now available on the
    Company´s website, www.octoplus.nl.

    Annual Report 2011
    During 2011, many of our clients and therefore also our business were negatively
    impacted by the current economic environment; however, OctoPlus has made
    significant progress in strengthening and professionalizing the organization,
    which we expect to positively impact our business results in the years to come.
    For the short term this has resulted in seven new contracts in 2011 and another
    four new contracts early 2012. In addition, we are happy to report that for OP-
    145 we have found two parties who are interested in further developing the
    product for various indications, which may result in limited manufacturing
    and/or licensing revenues.

    Key topics in the Annual Report 2011 are:
    * Our evaluation study for drug delivery into the eye with ESBATech, a
    Novartis company, progressed into a full development agreement in February
    2011
    * We expanded our efforts into a new strategic area, specialty generics, which
    comprises the development of copies of long-acting injectable drugs.

    It is our objective to create an operationally cash balanced business in the
    medium term, whereby the fee-for-service business generates the cash flow to
    support our infrastructure and provide the funds for co-investments and risk-
    sharing in projects such as specialty generics where we can capture upside
    potential for our shareholders. For the short term, we aim to generate at least
    20% organic growth in revenues in 2012, contributing to our overall strategy to
    build a company that is operationally cash-balanced, allowing a sustainable
    business with a large upside.

    Annual General Meeting of Shareholders to take place on 13 June in Leiden
    The Annual General Meeting of Shareholders will take place at OctoPlus´
    headquarters in Leiden on 13 June at 14:00. The meeting documents are now
    available in the Investor Relations section of the website www.octoplus.nl.

    During the meeting, the Supervisory Board will nominate three new Supervisory
    Board members for appointment: Staf van Reet, Catherine Moukheibir and
    Dharminder Singh Chalal.

    For further information, please contact:
    Rianne Roukema, Corporate Communications: telephone number +31 (71) 524 1071, or
    send an e-mail to Investor Relations at IR@octoplus.nl.

    About OctoPlus
    OctoPlus is a specialty pharmaceutical company focused on the development and
    manufacture of improved injectable pharmaceuticals based on our proprietary drug
    delivery technologies that exhibit fewer side effects, improved patient
    convenience and a better efficacy/safety balance than existing therapies.
    OctoPlus also focuses on the development of long-acting, controlled release
    versions of known protein therapeutics, peptides and small molecules, including
    specialty generics.

    The clinically most advanced product incorporating our technology is
    Locteron(®), a controlled release formulation of interferon alpha for the
    treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to
    Biolex in October 2008. Locteron is being manufactured for Biolex by OctoPlus
    and has completed Phase IIb clinical studies with superior clinical data versus
    current treatment.

    In addition, OctoPlus is a leading European provider of advanced drug
    formulation and clinical scale manufacturing services to the pharmaceutical and
    biotechnology industries, with a focus on difficult-to-formulate active
    pharmaceutical ingredients.

    OctoPlus is listed on NYSE Euronext in Amsterdam under the symbol OCTO. For more
    information about OctoPlus, please visit our website www.octoplus.nl.

    This document may contain certain forward-looking statements relating to the
    business, financial performance and results of the Company and the industry in
    which it operates. These statements are based on OctoPlus N.V.´s current plans,
    estimates and projections, as well as its expectations of external conditions
    and events. In particular the words "expect", "anticipate", "predict",
    "estimate", "project", "plan", "may", "should", "would", "will", "intend",
    "believe" and similar expressions are intended to identify forward-looking
    statements. We caution investors that a number of important factors, and the
    inherent risks and uncertainties that such statements involve, could cause
    actual results or outcomes to differ materially from those expressed in any
    forward-looking statements. In the event of any inconsistency between an English
    version and a Dutch version of this document, the English version will prevail
    over the Dutch version.


    Click here for the press release in PDF format:
    http://hugin.info/137076/R/1607029/509642.pdf

    This announcement is distributed by Thomson Reuters on behalf of
    Thomson Reuters clients. The owner of this announcement warrants that:
    (i) the releases contained herein are protected by copyright and
    other applicable laws; and
    (ii) they are solely responsible for the content, accuracy and
    originality of the information contained therein.

    Source: OctoPlus N.V. via Thomson Reuters ONE
    [HUG#1607029]

    Wertpapiere des Artikels:
    NL0000345718

    Schreibe Deinen Kommentar

     

    Disclaimer

    Nachrichtenquelle

    Weitere Nachrichten des Autors

    TitelLeser
    294
    245
    235
    201
    193
    190
    190
    184
    180
    173
    TitelLeser
    955
    655
    593
    503
    435
    421
    380
    379
    332
    315
    TitelLeser
    1102
    983
    955
    944
    869
    846
    655
    635
    603
    593
    TitelLeser
    17097
    14528
    10922
    10362
    9862
    8940
    7327
    7089
    6919
    6203

    Top Nachrichten aus der Rubrik